Antibiotic discovery continue to play a critical role in disease containment. Misuse and overuse of these drugs are the main drivers in the development of drug resistant pathogens. The World Health Organisation has declared that Antimicrobial resistance is one of the top 10 global public health threats facing humanity. There is the fears that if nothing is done, it might end the antibiotic era soon. In 2017 alone, over 9000 human deaths were caused by ESBL-producing Enterobacteriaceae in the USA. The ability of bacteria to develop newer strategies to acquire and disseminate resistance, can be traced as far back to 1940s when (R-factor) plasmid mediated antibiotic resistance was observed. They become resistant via the production of 𝛽-Lactamases and ESBLs enzymes which inactivate or modify antibiotics. Extended Spectrum 𝛽-Lactamases are enzymes whose rates of hydrolysis of the extended-spectrum 𝛽-Lactam antibiotics are >10 % than that for benzylpenicillin. Some bacteria may produce multiple ß-lactamases, which may reduce the effectiveness of ß-lactam/ ß-lactamase inhibitor combinations. These enzymes are susceptible to inhibition by 𝛽-Lactam inhibitors such as clavulanic acid, tazobactam, or sulbactam but have no hydrolytic activity against cephamycins and carbapenems. The production of acquired 𝛽-Lactamase and ESBL makes the choice of antibiotic treatment of infections caused by Gram-negative bacteria very limited, these have been the major causes of treatment failures, outbreaks of both community and hospital acquired infections, surgical failures, long hospital stay and huge economic losses, which continue to claim uncountable lives, especially in Nigeria and Africa where the health system are weak. The emergence of drug resistannt strains may be minimized by maintaining high levels of the drug in the tissues to inhibit mutants, administering two drugs that do not give cross-resistance, and by limiting the use of valuable second line ‘reserve drugs’ such .....

For quite a long time, mainly due to fewer treatment options, Clindamycin have been regarded as an alternative drug to effectively manage all Staphylococcus aureus infections. Strains with inducible clindamycin resistance (iMLSB phenotype) raise concerns because therapeutic failure may occur during treatment. Clindamycin is mostly regarded in treating serious infections that cannot be treated by other antibiotics, as it may cause colitis or mild diarrhea. A double disc diffusion test (D-test) for detecting inducible resistance to clindamycin in erythromycin-resistant methicillin-resistant S. aureus was performed by placing a 15µg erythromycin disc in proximity to a 2µg clindamycin disc in adjacent positions. For erythromycin-resistant isolates, D-test can help to determine whether clindamycin could be used as a therapeutic option (reported as susceptible when the D-test is negative or reported as resistant when the D-test is positive). Twenty (20) out of the 30 (thirty) isolates collected were confirmed to be determined by D-test as per CLSI guidelines. Fifteen (15) isolates were D-test Negative, 5 were resistant to both Erythromycin and Clindamycin, and none was D-test positive. D-test should be included as a mandatory method in routine disc diffusion testing to detect inducible clindamycin resistance in staphylococci for the optimum treatment of patients.